Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial

Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries

(2016) Giacomo Bellani et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Activation of A1-Adenosine Receptors Promotes Leukocyte Recruitment to the Lung and Attenuates Acute Lung Injury in Mice Infected with Influenza A/WSN/33 (H1N1) Virus

(2014) F. Aeffner et al.   JOURNAL OF VIROLOGY

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study

(2013) Geoff Bellingan et al.   Lancet Respiratory Medicine

Functional Disability 5 Years after Acute Respiratory Distress Syndrome

(2011) Margaret S. Herridge et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular mechanisms involved in adenosine-induced endothelial cell barrier enhancement

(2010) Nagavedi S. Umapathy et al.   VASCULAR PHARMACOLOGY

Has Mortality from Acute Respiratory Distress Syndrome Decreased over Time?

(2008) Jason Phua et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mortality Rates for Patients With Acute Lung Injury/ARDS Have Decreased Over Time

(2008) Massimo Zambon et al.   CHEST